Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

Fig. 5

Survival analysis based on immune score changes and pathologic complete response. Twenty-three patients with paired immune score showed (a), progression-free survival: hazard ratio (HR) 0.362, 95% confidential interval (CI) (0.060–2.184), p = 0.248; and (b), overall survival: HR 0.585, 95% CI (0.036–9.381), p = 0.702. c, Disease-free survival: HR 4.69e-16, 95% CI (0-NR), p = 0.210 (d), and overall survival: HR 4.84e-16, 95% CI (0-NR), p = 0.465 was shown in 25 patients who had curative surgery. HR and P calculated by log-rank test. Abbreviations: NR, not reached; pCR, pathologic complete response

Back to article page